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Abstract
Background: MYCN is a transcription factor that is expressed during the development of the neural crest and its
dysregulation plays a major role in the pathogenesis of pediatric cancers such as neuroblastoma, medulloblastoma and
rhabdomyosarcoma. MeCP2 is a CpG methyl binding protein which has been associated with a number of cancers and
developmental disorders, particularly Rett syndrome.
Methods and Findings: Using an integrative global genomics approach involving chromatin immunoprecipitation applied
to microarrays, we have determined that MYCN and MeCP2 co-localize to gene promoter regions, as well as inter/intragenic
sites, within the neuroblastoma genome (MYCN amplified Kelly cells) at high frequency (70.2% of MYCN sites were also
positive for MeCP2). Intriguingly, the frequency of co-localization was significantly less at promoter regions exhibiting
substantial hypermethylation (8.7%), as determined by methylated DNA immunoprecipitation (MeDIP) applied to the same
microarrays. Co-immunoprecipitation of MYCN using an anti-MeCP2 antibody indicated that a MYCN/MeCP2 interaction
occurs at protein level. mRNA expression profiling revealed that the median expression of genes with promoters bound by
MYCN was significantly higher than for genes bound by MeCP2, and that genes bound by both proteins had intermediate
expression. Pathway analysis was carried out for genes bound by MYCN, MeCP2 or MYCN/MeCP2, revealing higher order
functions.
Conclusions: Our results indicate that MYCN and MeCP2 protein interact and co-localize to similar genomic sites at very
high frequency, and that the patterns of binding of these proteins can be associated with significant differences in
transcriptional activity. Although it is not yet known if this interaction contributes to neuroblastoma disease pathogenesis, it
is intriguing that the interaction occurs at the promoter regions of several genes important for the development of
neuroblastoma, including ALK, AURKA and BDNF.
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Introduction
MYCN is a member of the MYC family of basic helix-loop-helix
(bHLH) transcription factors which regulate a diverse range of
cellular processes including proliferation, differentiation and
apoptosis [1]. High level amplification of MYCN occurs in
multiple pediatric cancers, and for neuroblastoma it is the most
important genetic prognostic indicator of poor clinical outcome
[2]. Further evidence that this transcription factor directly
contributes to tumorigenesis is provided by the development of
neuroblastoma-like tumors in a transgenic mouse model over-
expressing MYCN [3].
MYC family members heterodimerize with MAX at DNA
target sequences known as E-boxes, recruiting histone acetyltrans-
ferases (HAT) and activating gene expression [4]. MYC proteins
have also been shown to act as transcriptional repressors by
association with MIZ1 and function through the inhibition of SP1
activity [5,6]. Previously, we demonstrated that MYCN has a
significantly greater affinity for the CATGTG motif than for
CACGTG, which is significantly associated with c-MYC binding
sites [7,8]. We further demonstrated that aberrantly high levels of
MYCN promote the occupancy of weaker affinity E-box elements,
thus commandeering the functional role of other transcription
factors [9]. Aberrant target sites for MYCN binding are highly
enriched for genes that regulate aspects of the cell cycle, leading
predominantly to the up-regulation of these genes [10]. In addition
to directly affecting the expression of genes [9–16] and miRNAs
[17–20] by direct binding to promoter regions, changes in MYCN
levels undoubtedly also cause a cascade of secondary alterations to
the transcriptome.
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21436Genome-wide analysis of MYCN binding has also established a
more global role for MYCN as a mediator of chromatin structure
[21]. Consistent with this concept, we recently reported the
association of MYCN to regions of DNA hypermethylation,
through the integration of chromatin immunoprecipitation on
chip (ChIP-chip) and methylated DNA immunoprecipitation on
chip (MeDIP-chip) data [9]. The aberrant hypermethylation of
gene promoters is a well known mechanism for the transcriptional
silencing of tumor suppressor genes in many forms of cancer
including neuroblastoma [22–24]. We hypothesized that the
association between MYCN binding and regions of DNA
hypermethylation may be due to the action of an intermediate
methyl binding protein (MBD). Of the MBD proteins, MeCP2 is
essential in human brain development and has been linked to
several cancer types and neurodevelopmental disorders [25–28].
MeCP2 can selectively bind to methylated CpG residues, has been
shown to localize to inactive heterochromatic regions of DNA, and
interacts with the transcriptional repressor SIN3A to recruit
histone deacetylases (HDAC) to repress transcription of methyl-
ated promoters [29,30].
However, this classic model of MeCP2 as a transcriptional
repressor has been called into question, as methylated and
imprinted genes remain silent in MeCP2-deficient mice [31] and
gene expression profiling experiments failed to identify MeCP2
target genes regulated by methylated promoters [32]. A genome-
wide study of MeCP2 binding sites revealed that a large
percentage of MeCP2-bound gene promoters were unmethylated
and actively transcribed [33]. This result was supported by
Charhour et al. [34] in a study showing the interaction of MeCP2
with the transcriptional activator CREB1 at active promoters.
Additionally, a new model of MeCP2 function proposes that
MeCP2 can act as a transcriptional modulator, regulating
chromatin structure at distal methylation sites to modulate the
expression of active genes [35]. (For reviews, see [28,36])
In this study, we have carried out genome-wide analysis of
MYCN and MeCP2 binding sites in combination with methyla-
tion analysis, and have characterized a novel co-occupancy of
these proteins at promoter regions. Gene expression analysis of
bound promoters reveals differential expression levels of genes
bound individually by, or in combination with MYCN and
MeCP2.
Taken together, our results suggest that the majority of
hypermethylated MYCN sites are also bound by the methyl
binding protein MeCP2, that a greater number of MYCN/
MeCP2 positive sites occur outside of hypermethylated loci and
points to a role for MeCP2 in the modulation of gene expression in
MYCN amplified tumors.
Results
Co-occupancy of Genomic Regions by MYCN and MeCP2
We previously reported that MYCN co-localizes to regions of
hypermethylated DNA in neuroblastoma cell lines at a signifi-
cantly higher than expected frequency [9]. Here, we test the
hypothesis that this association might be due to the interaction of
MYCN with MeCP2, which is capable of directly binding to
methylated DNA and is known to play a role in cancer and
neurodegenerative disorders [26–28]. For an initial assessment of
this hypothesis, chromatin from the MYCN amplified neuroblas-
toma cell line Kelly was immunoprecipitated with an anti-MeCP2
antibody and then hybridized to the NimbleGen HG18 two-array
promoter set and to a custom designed tiling array representing
528 miRNA loci, as described previously [9]. In order to
determine the extent of MYCN and MeCP2 co-occupancy to
regions of hypermethylation, MeDIP-chip was also performed on
the Kelly cell line, using the above array platforms.
The MeCP2 ChIP-chip experiments were carried out in
duplicate on both the HG18 two-array promoter set and the
custom tiling array, and as illustrated in Figure S1A, B and C,
there was a high correspondence between the biological replicate
experiments for each microarray (r=0.89 and 0.92 for the two
array promoter set; r=0.88 for the custom tiling array). For
further validation of the MeCP2 ChIP-chip experiments, qPCR
primers were designed for seven randomly selected regions
showing enhanced MeCP2 binding on the ChIP-chip experiments
(Table S1). Six out of seven qPCR experiments showed .1.5 fold
enrichment of DNA sequence from the MeCP2 immunopreci-
pated sample relative to the IgG negative control, indicating that
the microarray results were of high quality (Figure S1D).
Comparison of our data to previously published MeCP2 target
sites [34,37] confirmed the presence of positive MeCP2 sites at the
promoter regions of SST, MEF2C, GPRIN1 and SGK (Figure S2 A–
D). In an additional study, Yasui et al. [33] performed ChIP-chip
analysis of MeCP2 precipitated DNA from the neuroblastoma cell
line SH-SY5Y using a custom designed microarray which tiled
26.3 Mb of imprinted and non-imprinted regions. In total, twelve
positive promoters from this data set were selected and examined
for MeCP2 binding in our results. Of these, eight were positive for
high confidence MeCP2 binding sites (Figure S2 E, F and Table
S1). The discordance found between data sets could be due to
genuine biological differences between the cell lines used or
technical issues such as the use of different MeCP2 antibodies for
immunoprecipitation. The results from MYCN ChIP-chip and
MeDIP experiments have also been rigorously validated, as
detailed previously [9].
Data generated from MYCN, MeCP2 ChIP-chip experiments
and MeDIP-chip experiments were analyzed using a custom Java
application to determine the extent of overlap between data sets.
Figure 1A depicts the number of significant MYCN, MeCP2 and
methylation sites which were in common and unique to each data
set from the promoter arrays, which includes an average coverage
of 4.7 kb around promoters for all annotated genes from RefSeq,
UCSC and the Mammalian Gene Collection. Similar to our
previous finding with the CpG Island/promoter array data set [9],
,11.5% (n=415) of MYCN sites were associated with hyper-
methylated promoters, representing a statistically significant
enrichment of MYCN at these sites (P,0.001). Approximately
75% (n=313) of these MYCN bound hypermethylated sites that
overlapped with MeCP2 binding sites. Remarkably, the co-
localization of MYCN/MeCP2 binding also occurred at promoter
regions lacking detectable hypermethylation, with 62% (n=2,222;
P,0.001) of MYCN sites being co-occupied by MeCP2. The
percentage of hypermethylated MeCP2 bound sites was evenly
split between those uniquely bound by MeCP2 (312 sites) and
those co-occupied by MYCN (313 sites) and the vast majority of
hypermethylated sites (82%, 3,323 sites) within Kelly are not
bound by MYCN or MeCP2.
Figure 1B depicts a three-way Venn diagram of the analyzed
custom tiling array datasets for miRNA regions. In contrast to the
promoter array results, a significant increase in the percentage of
MYCN sites associated with MeCP2 at hypermethylated regions
was observed. Of the 447 MYCN positive sites, 58% (n=261)
were co-occupied with MeCP2 at hypermethylated loci, compared
with just 9% (n=313) of MYCN sites identified with the promoter
array (Figure 1C). A similar shift was observed for the number of
MeCP2 sites associated with regions of hypermethylation. Of the
935 MeCP2 sites, 50% (n=470) were associated with hyper-
methylated loci, compared to just 6% (n=312) of MeCP2 sites
Association of MYCN and MeCP2 in Neuroblastoma
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21436identified using the promoter array (Figure S3). The increased
association of MYCN and MeCP2 to regions of hypermethylation
could be explained in part by the structural functions of these
molecules, as the miRNA array contains a significant amount of
inter/intragenic sequence.
In order to demonstrate that MYCN, MeCP2 and hypermethy-
lation co-localization occurs on the same chromosomal homolog,
we examined a terminally deleted region on the long arm of
chromosome 18 in the Kelly cell line (Figure 2A). Integration of
aCGH, ChIP-chip and MeDIP-chip data revealed an overlap of
MYCN, MeCP2 positive and DNA hypermethylated sites
confirming that this co-occupancy occurs on the same chromo-
some homolog (Figure 2B). To confirm specificity of the array data
derived from the immunoprecipitation experiments, we performed
negative control ChIP-chip experiments using normal mouse IgG.
The lower tracks in Figure 2B depict the results of that experiment
showing no overlap with the MYCN, MeCP2 and MeDIP sites.
Given that, 75% of hypermethylated MYCN promoter sites
were associated with MeCP2, and that 61% of the total MYCN
promoter sites were co-occupied by MeCP2 were non-hyper-
methylated regions, we carried out a co-immunoprecipitation
analysis using the MeCP2 antibody on nuclear extract obtained
from Kelly cells to determine if the association detected by ChIP-
chip data was due to the direct interaction of MYCN with MeCP2
protein. As illustrated in Figure 2C, MYCN co-immunoprecipi-
tated with MeCP2, leading us to conclude that the majority of
hypermethylated MYCN sites are also bound by the methyl
binding protein MeCP2. The reciprocal experiment, involving
MYCN antibody on nuclear extract, was uninformative as it was
not possible to resolve MeCP2 by electrophoresis from a similarly
sized IgG protein.
CpG Island Occupancy and Effects on Gene Expression
In the context of gene expression, hypermethylation generally
has a negative regulatory impact when occurring at CpG islands
within the promoter region of a gene, so it was of interest to
compare how the occupancy of MYCN and MeCP2 at such sites
impacts upon gene expression [Tables 1]. Among the 4,050
hypermethylated regions identified in Kelly using the two-array
promoter set, 1,077 were associated with a UCSC annotated CpG
island, representing a significant enrichment of hypermethylation
at CpG island sites. Consistent with a previous report, our data
shows that only 7.6% (383 sites) of the 5,010 MeCP2 binding sites
are associated with CpG islands [33]. Overall, there was a
significant under-representation of MYCN or MeCP2 at hyper-
methylated CpG islands, with 92% (984 sites) of such sites being
free of MYCN and MeCP2 binding. MeCP2, as a methyl binding
protein, had a higher association with hypermethylated CpG
islands (49 sites; 4.6% of hypermethylated CpG islands) than
MYCN (9 sites; 0.8%). Of the 313 hypermethylated sites co-
occupied by MYCN and MeCP2, only 35 sites were associated
with CpG islands, representing just 3.5% of the total hypermethy-
lated CpG island loci.
Gene expression analysis of the Kelly cell line was performed
using NimbleGen 4-plex 72K arrays in order to determine how
MYCN and/or MeCP2 binding might influence gene expression
Figure 1. Genome-wide analysis of MYCN and MeCP2 binding sites. (A) & (B) Three-way Venn diagrams displaying the number unique and
overlapping binding sites from MYCN and MeCP2 ChIP-Chip experiments along with the hypermethylated sites identified from MeDIP analysis of the
Kelly cell line, hybridized to (A) the two-array promoter set and (B) custom tiled arrays (B). (C) Pie charts representing the percentage of MYCN sites
which are unique to the MYCN dataset and which overlap sites enriched for MeCP2 binding and regions of hypermethylation.
doi:10.1371/journal.pone.0021436.g001
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Results from the expression microarrays had a high correlation
with selected TaqMan qPCR probes (r=0.95; P=0.001; Figure
S4). Median expression levels of genes whose promoter regions
varied in methylation status, CpG island status, MYCN or MeCP2
binding status were compared and evaluated by the Mann-
Whitney nonparametric test, as illustrated in Figure 3.
Overall, hypermethylation of promoter regions had a negative
impact on gene expression, as the median expression of genes at
non-hypermethylated promoters bound by MYCN was 2.6 fold
higher than hypermethylated promoters bound by MYCN
(P=0.02; Figure 3A). The median expression of genes with
non-hypermethylated promoters that were bound by MYCN was
,2.8-fold higher than similar promoters occupied by MeCP2
(P,0.0001; Figure 3B), consistent with MYCN having a positive
impact on transcription. Overall, the median expression of genes
with non-hypermethylated promoters and co-localization of
MYCN and MeCP2 was intermediate between those occupied
only by MYCN or MeCP2 (Figure 3B), indicating that MeCP2
interaction with MYCN can moderate gene expression. Interest-
ingly, there was no difference in median expression for MeCP2
bound promoters that were non-hypermethylated versus those that
were hypermethylated (Figure 3C); consistent with the hypothesis
that MeCP2 binding in the absence of hypermethylation can have
Figure 2. Analysis of MYCN, MeCP2 and hypermethylation in a region of hemizygous deletion. (A) Array CGH analysis of the Kelly cell
line showing a large 52.6MB terminal deletion on the long-arm of chromosome 18. (B) A tiled 70.5-kb section of the hemizygously deleted region on
chromosome 18, the upper panels display the raw log2 ratios and the identified, consistent binding sites for both MYCN and MeCP2. Peaks displayed
are considered high confidence binding sites with an FDR score of ,0.05 (red peaks) and 0.05-0.1 (orange peaks). Kelly MeDIP results are represented
by the panels in blue, including the raw log2 ratios, Kolomogorov-Smirnov test p-values (2log10), and the identified peaks of hypermethylation. The
lower panels show the results of a negative control experiment using normal mouse IgG. (C) A western blot of a Co-IP performed using anti-MeCP2
antibody.
doi:10.1371/journal.pone.0021436.g002
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when associated with hypermethylated CpG islands within
promoters relative to MeCP2 binding within promoters which
do not contain CpG islands (3.0-fold; P=0.03; Figure 3C). Among
hypermethylated CpG island promoters, median gene expression
was 3.4-fold higher for those co-occupied by MYCN and MeCP2
relative to those promoters only bound by MeCP2 (P=0.03;
Figure 3D), providing evidence that MYCN interaction can
Figure 3. Gene expression analysis of the kelly cell line. (A) A bar chart representing the median expression levels of genes whose promoter
regions are bound by MYCN. The dataset was subdivided into unique MYCN sites, hypermethylated MYCN sites and hypermethylated MYCN sites
associated with CpG Islands. (B – F) Similar analysis was performed for genes having promoters with different combinations of features (MYCN +/2;
MeCP2 +/2; methylation +/2 and/or CpG island +/2). Red arrows and green arrows denote the upper and lower quartiles of expression from the
overall gene expression microarray results. Genes with expression values which fall in the upper quartile are considered highly expressed while genes
which fall in the lower quartile are considered silent or expressed at low levels. Statistical analysis was performed using Mann-Whitney nonparametric
test.
doi:10.1371/journal.pone.0021436.g003
Table 1. CpG Island Occupancy.
Dataset No. of peaks No. of Methylated CpG Islands % of Peaks % of total Methylated CpGs P-value
MYCN MeDIP Peaks 102 9 8.82352941 0.835654596 0.0037*
MeCP2 MeDIP Peaks 312 49 15.7051282 4.549675023 0.0057*
MYCN MeCP2 MeDIP Peaks 313 35 11.1821086 3.249767874 ,0.0001*
Unbound MeDIP Peaks 3323 984 29.6117966 91.36490251 ,0.0001
Total MeDIP Peaks 4050 1077 26.5925926 n/a 0.00567
*Under-represented.
doi:10.1371/journal.pone.0021436.t001
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significant difference in median gene expression was detected
among the comparisons made (Figure 3 E and F). We conclude
that MeCP2 has an overall negative impact on gene expression,
while MYCN has a more positive influence. In addition,
interaction of MYCN with MeCP2 appears to mitigate the
negative effects of MeCP2 on gene expression, particularly at
promoter regions containing CpG islands.
Molecular Function of Downstream MYCN and MeCP2
Target Genes
In order to determine if there might be higher order functional
differences between genes with promoters uniquely bound by
MYCN or MeCP2 or jointly bound by both proteins, analysis of
these gene subsets was carried out using Ingenuity Pathway
Analysis (IPA) software. The top 5 enrichment categories for genes
uniquely bound by MYCN included cellular movement, cell
death, gene expression, cell cycle and cell signaling, all terms
which might be expected based on numerous prior studies of
MYCN (Figure 4A). Although these terms were most significantly
enriched for genes uniquely bound by MYCN, they were also
moderately enriched for genes uniquely bound by MeCP2 or co-
bound by MYCN/MeCP2 (p,0.05). For genes whose promoters
were uniquely bound by MeCP2, the top functional annotations
were lipid metabolism, small molecule biochemistry, vitamin and
mineral metabolism, cellular growth and cell signaling (Figure 4B).
Functional terms that were enriched for genes co-bound by
MYCN/MeCP2 considerably overlapped the functional terms
identified in the singly bound gene sets (Figure 4C).
Although there was broad overlap between the gene pathway
terms that were enriched in the three different gene sets, a more
detailed analysis of the functional classes listed under the terms was
informative. For example, genes involved with the cell cycle were
enriched for all three categories of promoters, however, genes
uniquely bound by MYCN were often involved in cell cycle
progression, such as CDC7, CDC23, CKS1B, NDC80 and NUF2
whereas those uniquely bound by MeCP2 were often involved
with cell cycle arrest or senescence. This observation is consistent
with our finding that genes uniquely bound by MYCN are
generally more over-expressed than genes uniquely bound by
MeCP2. Further analysis of the broad functional category of cell
death revealed that genes co-bound by MYCN/MeCP2 were
enriched for the subcategories of ‘‘apoptosis of neuroblastoma cell
lines’’ and ‘‘survival of neuroblastoma cell lines’’. These subcat-
egories included many genes known to be important in
neuroblastoma pathogenesis, including ALK, AURKA and BDNF
(Figure S5). As previously discussed, genes that are co-bound by
MYCN/MeCP2 generally have expression levels that are
intermediate between singly bound promoters. Within the cellular
movement category, several genes that were identified as bound by
MYCN had a functional role in cellular migration and invasion
including the non-receptor tyrosine kinase PTK2. PTK2 has been
implicated in NB and shown to be a direct target of MYCN [38],
with higher expression levels of this protein being positively
correlated with MYCN amplified cell lines [39]. Inhibition of this
survival factor has been shown to inhibit migration and invasion of
NB cell lines [40] and leads to a decrease in cell viability [41].
Motif Analysis Reveals Differences in E-box Frequencies
at Sites Bound by MYCN and MeCP2
Both c-MYC and MYCN are known to bind to the canonical
CACGTG E-box motif and a number of other non-canonical
motifs, although Murphy et al. [ 9 ]d e m o n s t r a t e dt h a tt h e
frequency of MYCN binding at CACGTG sites is substantially
lower than what was demonstrated for c-MYC by Zeller et al.
[8]. In contrast to c-MYC, MYCN appears to occupy sites
with a higher frequency of CATGTG and CACCTG [9].
Here, we have determined whether the frequency of E-box
usage by MYCN is dependent upon its interaction with
MeCP2 at regions with and without detectable levels of DNA
methylation.
Using supervised motif analysis of the promoter array results,
we examined the frequency of all combinations of CANNTG
E-box motifs across the various intersections of the MeCP2,
MYCN and MeDIP datasets, along with the frequency of each
motif in the background data set (all sequences contained on the
promoter array; Figure 5). For hypermethylated regions co-
occupied by MeCP2 and MYCN, a higher frequency of
CATGTG (2.3-fold above background; P,1.2e-04) and
CACCTG (2.2-fold above background; P,6.5e-06) occurs,
similar to our previous analysis based on MYCN binding alone
[9]. There was no significant enrichment for the MeCP2 A/T
rich consensus motif, as previously described by Klose et al [42].
Interestingly, the classic c-MYC binding motif CACGTG (4.3-
fold above background; P,9.9e-05) was highly enriched where
MeCP2 was bound to hypermethylated regions in the absence of
MYCN (Figure 5F). These sites were also enriched for the
CACCTG motif (2.3-fold; P,1.6e-06) and the MeCP2 A/T rich
consensus motif (1.4-fold; P,9.9e-07). Similar analysis of the
custom tiling array revealed that such a shift in E-box preference
is not observed in hypermethylated binding sites in intergenic
regions (Figure S6).
For unmethylated MYCN and MeCP2 genomic sites, there was
less enrichment for E-boxes in general (1.3-fold maximum
enrichment), with no clear preference for any particular E-box
variant. This was also the case for regions only occupied by
MeCP2 (1.2-fold).
Bioinformatic Prediction of DNA Binding Proteins
Associated with Sites Bound by MYCN and MeCP2
To investigate other potential transcription factors that might be
associated with MYCN/MeCP2 co-binding sites, we determined if
other transcription factor binding motifs were significantly over-
represented. We then cross referenced these significance values
with the mRNA expression for these genes to establish which
transcription factors were expressed in Kelly cells. The mRNA
expression for each transcription factor was plotted against the
significance of its motif enrichment [2log10 (P-value); Figure 6A &
B]. Transcription factors with mRNA expression greater than the
median and whose motifs were significantly enriched (p,0.05) in
all sites co-bound by MYCN and MeCP2 are represented in the
upper right quadrant of Figure 6A. A similar analysis was also
carried out for MYCN/MeCP2 binding at sites that were
hypermethylated (Figure 6B). By way of further external validation
of this model, we examined whether any known or predicted
interactions existed between these putatively co-associated tran-
scription factors. This is illustrated in Figure 6C and D as a
network in which the thickness of the lines connecting the nodes
represents the confidence of the given interaction (see methods).
Discussion
Using ChIP-chip methods we have identified a novel pattern of
high frequency co-localization of the MYCN transcription factor
and the MeCP2 methyl binding protein to genomic sites in
neuroblastoma Kelly cells. Through a co-immunoprecipitation
Association of MYCN and MeCP2 in Neuroblastoma
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has occurred, but whether both, or only one protein, is binding to
DNA is uncertain. The interaction of MeCP2 with another
transcription factor, CREB1, has also been documented by
Chahrour et al. [34] using mass spectroscopy analysis of protein
immunoprecipitated from brain extracts of wild-type mouse with an
anti-MeCP2 antibody. Consistent with the findings of Chahrour
et al. [34], we detected a statistically significant enrichment for the
CREB1 DNA binding motif at sites that were positive for MYCN,
MeCP2 and methylation. Our own co-immunoprecipitation
reactions revealed that MeCP2 is capable of immunoprecipitating
MYCN; however MYCN was not detected in the analysis carried
out by Chahrour et al. [34]. This disparity is likely due to the low
expression levels of MYCN in the brains of adult mice, our co-
immunoprecipitations were carried out on nuclear extracts from a
MYCN amplified cell line expressing high levels of the protein.
Figure 4. Pathway analysis of target genes. Comparison analysis of the top significant biological functions for (A) genes whose promoters are
occupied by MYCN (B) genes whose promoters are occupied by MeCP2 (C) genes whose promoters are co-occupied by MYCN and MeCP2. Each panel
represents the top five biological functions of each group of genes, and compares the significance of each of the functions across datasets. The
significance scores for each biological function are represented as –log(P-value). The analysis was performed using the IPA software, significant
biological functions were identified as having a p-value of less than P,0.05 (represented by a red bar).
doi:10.1371/journal.pone.0021436.g004
Association of MYCN and MeCP2 in Neuroblastoma
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21436Chahrour et al [34] also reported on gene expression analysis of
braintissues fromMeCP2-null miceand from transgenicmice which
over-express MeCP2. In contrast to the classical model, they noted
that gain of MeCP2 caused significantly more activation than
repression, while loss of MeCP2 caused an increase in repression
and a decrease in activation. Sequential ChIP analysis of chromatin
immunoprecipitated with CREB1 and MeCP2 followed by
luciferase reporter and gene expression assays confirmed that the
two factors associated with the promoter regions of specific genes
(including Sst and Mef2c) and activated transcription. Our own
analysis of gene expression indicates that many genes with MeCP2
bound promoters are transcriptionally active. However, our results
also reveal the influence of MYCN, which is expressed at high levels
in Kelly. As expected from a transcriptional activator, the group of
genes bound by MYCN but not MeCP2 had significantly higher
levels of expression (,2.8-fold, P,0.0001) than those bound by
MeCP2 alone. Groups of genes bound in combination with MYCN
and MeCP2 had median expression that was intermediate to those
bound by only MYCN or MeCP2. These results suggest that both
proteins can act as modulators of transcription.
Previous ChIP-chip analysis of MeCP2 binding sites within the
neuroblastoma cell line SH-SY5Y by Yasui et al. revealed that the
majority of MeCP2 binding sites were unmethylated, occurred
outside of CpG islands, and that downstream genes were actively
expressed [33]. These results challenged the dominant model of
MeCP2 as a functional repressor of transcription, acting by
binding to methylated CpG dinucleotides, facilitating the recruit-
ment of corepressors and chromatin remodeling complexes
[29,30]. Our results from the promoter arrays also indicate that
MeCP2, as well as MYCN, bind to a relatively small proportion of
hypermethylated promoters [11.5% of MYCN sites, 12% of
MeCP2 sites]. Interestingly, similar analysis of the custom tilling
array, which contained a high proportion of inter/intragenic DNA
sequences, revealed a much higher association with regions of
hypermethylation for both MYCN and MeCP2. [74.9% of
MYCN sites, 77.6% of MeCP2 sites]. The higher frequency of
MYCN/MeCP2 co-localization at hypermethylated non-promot-
er regions is consistent with both proteins playing a role in the
maintenance of chromatin structure.
An intriguing possibility is that MYCN and MeCP2 can co-
operate to regulate gene expression by altering higher-order
chromatin structure. Several recent studies using chromosome
conformation capture (3C) techniques have shown that distally
located cis-regulatory elements can be brought into proximity to
the promoter of active genes, indicating that a chromatin loop
forms to allow the adjacent association of both elements. A study
of the imprinted Dlx5/Dlx6 locus using 3C combined ChIP with
an anti-MeCP2 antibody, demonstrated the MeCP2 was required
Figure 5. Assessment of motif enrichment at unique and commonly bound MYCN and MeCP2 sites from the promoter array data
set. Here we illustrate the frequency, relative to background, of the various classes of canonical E-boxes (CANNTG) in non-methylated sites bound by
MYCN alone (A), MeCP2 alone (C) and both MYCN and MeCP2 (B); and methylated sites bound by MYCN alone (D), MeCP2 alone (F) and both MYCN
and MeCP2(E). We also include the putative MeCP2 binding motif proposed by Klose et al. (37). Motifs with 1.5 fold change over background and
P,0.05 are highlighted. In non-methylated regions we see .1.5 fold-enrichment for CATCGT and CATGTG motifs. In methylated regions we see a
significant preference for the CATGTG motif at locations bound by MYCN. There is a significant preference for the classical CACGTG E-box motif at
methylated locations bound by MeCP2 alone.
doi:10.1371/journal.pone.0021436.g005
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deficient mice had increased expression of Dlx5 and Dlx6 as a
result of aberrant loop formation. The influence of MeCP2 in the
formation of chromatin loops does not seem to be limited to
transcriptional silencing, however, as gene expression and ChIP-
chip analysis of several genes, including JUNB, within the NB cell
line SH-SY5Y, indicate that these genes are modulated by distal
and proximal MeCP2 binding sites [33]. Although the SH-SY5Y
cell line is not MYCN amplified, it does over-express MYCN,
suggesting that the MYCN and MeCP2 could co-operate to
modulate the expression of JUNB. Our own ChIP-chip analysis of
JUNB in the Kelly cell line reveals several putative overlapping
MYCN and MeCP2 binding sites around the promoter region of
JUNB which are similar to those previously described in SH-
SY5Y. The mechanism that modulates chromatin looping remains
poorly understood, but it is thought that changes in chromatin
flexibility are necessary to allow loop formation. It has been
suggested that chromatin flexibility is regulated by histone
Figure 6. Putative association of transcription factor binding motifs at commonly bound MYCN/MeCP2 sites. For (A) and (B), plots
show increasing expression of transcription factor mRNA on the X-axis and increasing enrichment for motifs on the Y-axis. For each plot, the upper
right quadrant represents greater than median expression for a transcription factor and significant over-representation of the respective binding
motif (P,0.05) for (A) all commonly bound MYCN/MeCP2 sites and (B) commonly bound MYCN/MeCP2 sites only at hypermethylated promoter
regions. (C) and (D) illustrate potential protein interactions for the transcription factors whose motifs were over-represented (from A and B,
respectively) based on available evidence from the String database. The thickness of the edges between the nodes represents the confidence of the
interaction. The MYCN/MeCP2 interaction identified in this report is shown as a dashed red line.
doi:10.1371/journal.pone.0021436.g006
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increased flexibility following temperature change, and is more
accessible to DNase digestion [44]. MYC family members have
been shown regulate histone acetylation through the recruitment
of HATs such as TIP60 [45] and GCN5 [46] at a number of
genetic loci. Additionally, a study by Cotterman et al. revealed that
over 90% of the identified genomic euchromatic marks,
acetylation of histone H3K9 and trimethylation of H3K4, were
dependent upon MYCN expression [21].
The MYC family of transcription factors have been previously
associated with specific DNA binding sequence motifs known as E-
boxes. We have previously shown a preference of certain E-box
motifs (CATGTG, CATTTG, CATCTG and CAACTG) in the
MYCN amplified state. An E-box analysis of hypermethylated
regions which were MeCP2 positive and MYCN positive, revealed
enrichment for both CATGTG and CACCTG motifs. Interest-
ingly, the classic E-box motif CACGTG was highly enriched (4.3
fold) where MeCP2 was bound to hypermethylated regions in the
absence of MYCN. This is consistent with the report by Perini et
al [47] that MYCN does not bind to methylated CACGTG E-
boxes. In addition, the enrichment of the CACGTG motif at these
MeCP2 sites would suggest a potential interaction with a basic
helix-loop-helix protein such as c-MYC, a hypothesis that requires
further testing. Previously, Westermann et al. [48] reported an
anti-correlation between MYCN and c-MYC expression, although
both transcription factors had a redundant core set of direct
MYCN/c-MYC target genes in neuroblastoma cells.
In conclusion, our results indicate that MYCN and MeCP2
protein interact and co-localize to similar genomic sites at very
high frequency. Overall, genes with MYCN and MeCP2 bound
promoters have a median expression that is intermediate between
genes that are uniquely bound by either MYCN or MeCP2. Our
results also support the concept that MeCP2 has a repressive effect
on transcriptional activity, except when it is interacting with
MYCN and potentially other transcriptional activators. Currently,
it is not known if this interaction contributes towards neuroblas-
toma disease pathogenesis or represents an important and normal
process occurring in the development of the neural crest. Further
studies are warranted to address these questions, particularly since
the interaction of these two proteins occurs at the promoters of
several genes that are important for the development of
neuroblastoma, including ALK, AURKA, and BDNF.
Materials and Methods
Cell Culture
Kelly cells were obtained from the European Collection of
Animal Cell Cultures (Porton Down, United Kingdom) and were
cultured in RPMI-1640 supplemented with 2 mM glutamine, 10%
fetal bovine serum and penicillin/streptomycin. The Kelly
neuroblastic cell line, derived from the metastatic tissue of a female
neuroblastoma patient, contains an amplification of the MYCN
oncogene and expresses elevated levels of MYCN mRNA and
protein [49]. A detailed DNA copy number profile of this cell line
has been previously reported [50].In order to obtain sufficient
material for ChIP-chip, large scale cultures were grown using
hyperflask cell culture vessels (Corning Life Sciences, Corning, NY).
Small scale cultures were maintained in T-75 culture flasks for
qPCR, microarray expression analysis, co-immunoprecipitation
and Western blot experiments.
Chromatin Immunoprecipitation to Microarrays
ChiP-chip analysis was performed as previously described by
Murphy et al. [9]. Briefly, protein-DNA interactions were
preserved by cross-linking cells by incubation with a 1%
formaldehyde solution for 10 min at room temperature. After
nuclear isolation, the chromatin was sonicated to generate
fragments of approximately one kilobase in length. Chromatin
immunoprecipitations were performed using 10 mg of rabbit
polyclonal anti-MeCP2 antibody (Abcam, Cambridge, UK)
complexed with M-280 Sheep anti-Rabbit Dynabeads and a
DynaMag
TM magnetic particle concentrator (Invitrogen, Carls-
bad, CA). Purified ChIP and input DNA was differentially labeled
with Cy5 and Cy3 random primers, respectively (TriLink
BioTechnologies, San Diego, CA) and co-hybridized to the
HG18 two-Array Promoter set and a custom designed array
manufactured by Roche NimbleGen. The promoter arrays
included an average coverage of 4.7 kb around promoters, with
a median probe spacing of 102 bp for all RefSeq genes, UCSC
known genes and the Mammalian Gene Collection. The custom
array was designed to include tiled sequence of 50-kb 59 and 20-kb
39 of 528 miRNAs. Scanning was performed using the Axon
4000B microarray scanner with GenePix 6.0 (Molecular Devices,
Sunnyvale, CA). Image analysis and peak detection was performed
using the Nimblescan Version 2.4 software and visualized using
Signalmap Version 1.9. Enriched sites were identified using the
normalized log2 ratios and the NimbleScan peak finding function.
An in-built peak analysis algorithm detected significantly enriched
regions that had at least 4 probes above a threshold value of log
2.0. These enriched regions were then identified as ‘‘peaks’’ and a
false discovery rate (FDR) score was assigned. Enriched sites with a
false discovery rate (FDR) of less than 0.1, which were shared
across duplicate ChIP reactions were filtered using an in-house
Java application and selected for further analysis. Raw log2 ratio
data for array experiments are available at www.ebi.ac.uk/
arrayexpress (Accession E-MTAB-621).
Methylated DNA Immunoprecipitation to Microarrays
The protocol used was as previously described by Weber et al.
[51] with adaptations [23]. Briefly, 5 mg of isolated DNA was
sonicated to 400–800 bp in length. The sonicated DNA (4 mg) was
incubated overnight with 10 mg of anti-59 methyl-cytidine
antibody (Eurogentec, Seraing, Belgium) to immunoprecipitate
methylated sequences. SYBR green qPCR analysis was performed
prior to microarray hybridization in order to confirm enrichment
of methylated sequences (Figure S7). The methylated H19 locus
was used as the control and fold enrichment of this locus was
determined relative to the unmethylated H3B locus [52]. Input
control and MeDIP DNA samples were labeled using Cy3 and
Cy5 random primers, (TriLink BioTechnologies, San Diego, CA)
respectively, and co-hybridized to a custom miRNA array and to
the HG18 two-Array promoter set from Roche NimbleGen.
Arrays were scanned using the GenePix 4000B scanner and
analyzed using the Nimblescan software Version 2.4. Normalized
log2 ratio data was calculated and a one-sided Kolmogorov-
Smirnov (KS) test using a sliding window of 750 bp was used to
determine whether the probes were drawn from a significantly
more positive distribution of intensity log-ratios than those on the
rest of the microarray. Each probe was assigned a –log10 p-value
from the windowed KS test and hypermethylated sites of
enrichment were detected by searching for at least two probes
with a minimum –log10 p-value of two. Peaks within 500 bp of
each other were merged and SignalMap version 1.9 was used to
visual the resulting data files.
Gene Expression
Total RNA was extracted from Kelly cells using the RNeasy
Mini Kit (Qiagen, Valencia, CA) and the complete removal of
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RNase-free DNase set (Qiagen, Valencia, CA). The integrity of the
RNA was confirmed using the Experion RNA StdSens Analysis
Kit (Bio-Rad, Hercules, CA). Using the Superscript Double-
Stranded cDNA Synthesis Kit from Invitrogen (Invitrogen,
Carlsbad, CA), 10 mg of total RNA was used to synthesize
double-stranded cDNA. The Cy3 fluorophore (Amersham Biosci-
ences, Amersham, UK) was used to label the cDNA and 4 mgo f
this labeled cDNA was hybridized to the homo sapiens 4672 K
Gene Expression Array (Roche NimbleGen, Madison, WI). Arrays
were scanned using GenePix 6.0 software on the Axon 4000B
microarray scanner. Data analysis was performed using the
expression robust multi-array module of Nimblescan Version
2.4. The raw data from the gene expression array experi-
ments are available at www.ebi.ac.uk/arrayexpress (Accession
E-MEXP-3121).
SYBR Green Q-PCR Analysis
Regions of enrichment identified from duplicate ChIP-chip
experiments were validated by SYBR green Q-PCR analysis.
Designed PCR primers mapping to the enriched regions were
manufactured by MWG (Table S2). Negative control primers
mapping to un-enriched genomic regions were also designed. Q-
PCR analysis was performed in duplicate on enriched DNA from
anti-MeCP2 immunoprecipitations and un-enriched DNA from
immunoprecipitations performed using normal rabbit IgG. The
comparative Ct method was used to determine the relative level of
enrichment (RQ) for each of the target regions.
RT-PCR Validation (Taqman Probes)
Taqman gene expression assays for CDC7 (Hs00177487_m1),
CDC25A (Hs00947994_m1), MeCP2 (Hs00172845_m1), MYCN
(Hs00232074_m1), c-MYC (Hs00153408_m1), TP53 (Hs99999
147_a1), TERT (Hs99999022_m1) and b-Actin (HS99999903_m1)
were obtained from Applied Biosystems and were used to validate
the gene expression array results. Analysis was performed using
the 7900HT Fast Realtime System (Applied Biosystems, Foster
City, CA). The results of the gene expression array were correlated
with the Ct values of gene expression probes using Spearman’s
rank correlation coefficient.
Co-Immunnoprecipitation Analysis
Co-immunoprecipitations were performed using a modified
version of the Universal Magnetic Co-IP Kit protocol (Active-
Motif, Carlsbad CA). Briefly, 5610
6 Kelly cells were harvested
from a T75 cell culture flask and nuclei were isolated by re-
suspending the cells in a complete hypotonic buffer for 15 min on
ice. After the addition of detergent, the cells were centrifuged at
14,000 x g in a pre-chilled microcentrifuge and the nuclear fraction
was retained. The nuclei were enzymatically sheared by
incubation at 37uC for 10 min after re-suspension in complete
digestion buffer containing an enzymatic shearing cocktail. The
reactions were stopped with the addition of 0.5 M EDTA and,
after centrifugation, the supernatant containing the digested nuclei
was retained. The nuclear extract (500 mg) was incubated with
5 mg of rabbit polyclonal MeCP2 antibody (Abcam, Cambridge,
UK) or 5 mg of normal rabbit IgG (Santa Cruz Biotechnology,
Santa Cruz, CA) on a rotating platform for 4 h at 4uC. Protein G
magnetic beads were added to the reactions and the incubation
was continued using the same conditions for a further hour. After
incubation, the protein beads were precipitated using a magnet
and after washing, the protein complexes were eluted by re-
suspending the beads in 20 ml of Laemmli buffer and incubating
the samples at 100u for three minutes. Each sample (10 ml) was
loaded onto a 10% SDS-PAGE gel and resolved by electrophor-
esis.The protein was transferred to a nitrocellulose membrane
which was then blocked overnight at 4uC with a 5% solution of
BSA. Blots were probed with a 1 in 500 dilution of B8.4.B (Santa
Cruz Biotechnology, Santa Cruz, CA) antibody, followed by a 1 in
500 dilution of Clean-Blot IP Detection Reagent (HRP) (Thermo
Scientific, Waltham, MA).
Ingenuity Pathway Analysis
Lists of genes which were identified as bound uniquely by, or in
combination with, MYCN and MeCP2 using an in-house Java
based software program. These lists were then imported into
Ingenuity Pathway Analysis (IPA) version 8.8 (http://www.
ingenuity.com). To identify the top functions of lists bound by
MYCN and MeCP2, the biological functional analysis was
performed on all datasets separately. The results of this analysis
were compared across datasets, using Fisher’s Exact test, biological
functions were deemed to be significant if P,0.05.
Transcription Factor Binding Site Analysis
DNA sequence data for the processed ChIP regions for each
cell line were retrieved from the UCSC database. Phylogeneti-
cally conserved sequence between Human (HG18) and Mouse
was selected for motif analysis. The occurrence of DNA binding
motifs was assessed in relation to their background frequencies
within the sequence tiled on the promoter array. Significance for
over- or under-representation was assessed using P-values based
on Chi-square test. Transcription factor motif enrichment was
assessed by examining occurrence of 482 transcription factor
binding motifs (from 358 transcription factors), represented by
their position-weight-matrices (PWM), in the conserved DNA
sequences from the various peak datasets. We then calculated
over-representation of each motif compared to our promoter
array background and generated a significance value from the
Chi-squared test. The String database was used to retrieve
information on known and predicted proteins interactions
(http://string-db.org) [53]. This information is based on several
types of evidence retrieved from areas such as direct experimental
and text mining.
Supporting Information
Figure S1 Pair-wise comparisons of log2 ratios from replicate
ChIP-chip experiments from the Kelly cell line hybridised to the
promoter two-array set (A & B) and the custom tiled array (C).
Correlation scores above R=0.85 were observed between
replicate experiments confirming that the experiments reproduc-
ibly detected MeCP2 binding sites. (D) SYBR Green qPCR
validation of positive MeCP2 binding sites. Fold enrichment of
positive MeCP2 target sites is displayed. Experiments were carried
out in duplicate using the standard delta delta Ct method. Results
are plotted relative to a region negative to MeCP2 Binding (H3B)
which is set to 1.
(TIF)
Figure S2 Identification of MeCP2 binding within the promoter
regions of previously published target genes (A) SST, (B) GPRIN1,
(C) MEF2C (D) SGK (E) SNRPN and (F) BDNF. The base pair
position of the promoters is indicated by the scale across the top of
the panels. The fluorescent intensity of the probes across replicates
is expressed as log2 ratios and is represented as the tracks with
green bars. Statistically significant MeCP2 binding sites are
represented as red bars. The position of the genes and the tiled
region on the array are indicated by the two lower tracks.
(TIF)
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which are unique to the MeCP2 dataset and which overlap sites
enriched for MYCN binding and regions of hypermethylation.
(TIF)
Figure S4 Gene expression validation of nimblegens 4-plex 72K
arrays. Taqman gene expression probes were selected for CDC7,
CDC25A, MeCP2, MYCN, MYC, P53, TERT and b-Actin. The Ct
values for these probes were correlated with the expression values
obtained for each of these genes on the array platform using
Spearman’s Rank Correlation Test. (Spearman’s r=0.95,
p=0.0011)
(TIF)
Figure S5 Co-localization of MYCN and MeCP2 at the
promoters of neuroblastoma relevant genes. (A) promoter region
of ALK (B) promoter region of BDNF (C) promoter region of
AURKA. Data from replicate MYCN and MeCP2 ChIP-chip
experiments is presented. Red bars represented regions with
statistically significant over-representation of the respective
proteins.
(TIF)
Figure S6 Assessment of motif enrichment at unique and
commonly bound MYCN and MeCP2 sites in intergenic regions
identified from the miRNA custom tiling array data set. Here we
illustrate the frequency, relative to background, of the various
classes of canonical E-boxes (CANNTG) in non-methylated
intergenic sites bound by MYCN alone (a), MeCP2 alone (c)
and both MYCN and MeCP2 (b); and methylated intergenic sites
bound by MYCN alone (d), MeCP2 alone (f) and both MYCN and
MeCP2(e). We also include the putative MeCP2 binding motif
proposed by Klose et al (37). Motifs with 1.5-fold change over
background and P,0.05 are highlighted.
(TIF)
Figure S7 qPCR showing enrichment of the imprinted H19
gene promoter relative to the non-methylated H3B promoter
following MeDIP from Kelly cells.
(TIF)
Table S1 Comparison of MeCP2 ChIP-chip results with Yasuai
et al 2008.
(XLSX)
Table S2 PCR Primers.
(XLSX)
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